Holen Sie sich die Stockscreener-App
3.625
0.69%
0.025
Handel nachbörslich:
3.63
0.005
+0.14%
Schlusskurs vom Vortag:
$3.60
Offen:
$3.59
24-Stunden-Volumen:
493.06K
Relative Volume:
1.25
Marktkapitalisierung:
$275.57M
Einnahmen:
$351.37M
Nettoeinkommen (Verlust:
$-174.01M
KGV:
-1.7512
EPS:
-2.07
Netto-Cashflow:
$-126.94M
1W Leistung:
+4.47%
1M Leistung:
+16.94%
6M Leistung:
+5.99%
1J Leistung:
+12.23%
1-Tages-Spanne:
$3.59
$3.80
1-Wochen-Bereich:
$3.425
$3.80
52-Wochen-Spanne:
$2.455
$4.145
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Firmenname
Atea Pharmaceuticals Inc
Sektor
Branche
Telefon
857-204-8109
Adresse
225 FRANKLIN STREET, BOSTON
Vergleichen Sie AVIR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
3.625 | 275.57M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-13 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-10-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-24 | Eingeleitet | JP Morgan | Overweight |
| 2020-11-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Atea Pharmaceuticals Inc Aktie (AVIR) Neueste Nachrichten
Here's Why We're Not At All Concerned With Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation - Yahoo Finance
Bank of America Corp DE Boosts Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Millennium Management LLC Invests $75,000 in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Squarepoint Ops LLC Buys 35,053 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Two Sigma Investments LP - Defense World
Jane Street Group LLC Decreases Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Public Employees Retirement System of Ohio Trims Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Ameriprise Financial Inc. Sells 11,900 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
ProShare Advisors LLC Buys 6,163 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Layoff Tracker: Keros Cuts 45% of Workforce Along With Pulmonary Hypertension Drug - BioSpace
BNP Paribas Financial Markets Buys New Shares in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Northern Trust Corp Boosts Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
D. E. Shaw & Co. Inc. Purchases 62,505 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Wall Street Zen Upgrades Atea Pharmaceuticals (NASDAQ:AVIR) to “Hold” - Defense World
Price T Rowe Associates Inc. MD Purchases 3,882 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Q2 EPS Forecast for Atea Pharmaceuticals Reduced by Analyst - Defense World
Dimensional Fund Advisors LP Has $3.27 Million Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Transcript : Atea Pharmaceuticals, Inc.Special Call - marketscreener.com
Atea Pharmaceuticals Advances HCV Treatment Trials - TipRanks
Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Wells Fargo & Company MN Increases Stock Position in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals (AVIR) to Release Earnings on Monday - Defense World
Atea reports high efficacy in Phase 2 HCV drug trial By Investing.com - Investing.com Nigeria
Barclays PLC Increases Stake in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals (AVIR) Reveals Promising Phase 2 Results for Hepatitis C Treatment | AVIR Stock News - GuruFocus
Atea reports high efficacy in Phase 2 HCV drug trial - Investing.com
Atea Pharmaceuticals Announces Full Results from Phase 2 - GlobeNewswire
Atea Pharmaceuticals Announces Full Results From Phase 2 Study Of Regimen Of Bemnifosbuvir And Ruzasvir For Treatment Of Hepatitis C Virus (HCV) Presented At EASL Congress 2025 - marketscreener.com
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025 - Stock Titan
A stock that deserves closer examination: Atea Pharmaceuticals Inc (AVIR) - uspostnews.com
Atea Pharmaceuticals (AVIR) Organizes HCV Treatment Panel & Announces Q1 Results | AVIR Stock News - GuruFocus
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025 - The Manila Times
JPMorgan Chase & Co. Buys 314,015 Shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Geode Capital Management LLC Lowers Stock Holdings in Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) - Defense World
Atea Pharmaceuticals Inc (AVIR) produces promising results - uspostnews.com
Financial Health Report: Atea Pharmaceuticals Inc (AVIR)’s Ratios Tell a Tale - DWinneX
Atea Pharmaceuticals (AVIR) to Reveal Phase 2 Study Results at E - GuruFocus
Atea Pharmaceuticals to Present New Data Showcasing Potential Best-in-Class Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus at EASL Congress 2025 - GlobeNewswire
AVIRAtea Pharmaceuticals, Inc. Latest Stock News & Market Updates - Stock Titan
A better buy-in window may exist right now for Atea Pharmaceuticals Inc (AVIR) - Sete News
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Sold by Vanguard Group Inc. - Defense World
Atea Pharmaceuticals expands board, authorizes stock buyback By Investing.com - Investing.com Canada
Latham & Watkins Advises Atea Pharmaceuticals in Agreement With Radoff-JEC Group - Latham & Watkins LLP
Atea Pharmaceuticals Appoints Howard H. Berman To Board - citybiz
Atea Pharmaceuticals Announces Board Changes and Share Buyback - TipRanks
Atea Pharmaceuticals Board Approves $25 Million Share Repurchase Program - marketscreener.com
Atea Pharmaceuticals expands board, authorizes stock buyback - Investing.com
Atea Pharmaceuticals says strategic alternatives process ‘ongoing’ - TipRanks
Atea Pharmaceuticals Appoints Howard H. Berman To Board Of Directors And Announces Share Repurchase Program - marketscreener.com
Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program - GlobeNewswire
Finanzdaten der Atea Pharmaceuticals Inc-Aktie (AVIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atea Pharmaceuticals Inc-Aktie (AVIR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
506,497 |
| Duncan Barbara Gayle | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Polsky Bruce | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
95,206 |
| Adams Jerome M. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Lucidi Bruno | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
112,750 |
| BERGER FRANKLIN M | Director |
Dec 10 '24 |
Sale |
2.85 |
359,606 |
1,023,475 |
451,897 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):